Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2020
Price :
$35
*
At a glance
- Drugs Nangibotide (Primary)
- Indications Septic shock
- Focus Adverse reactions
- Sponsors Inotrem
- 02 Jun 2020 According to an Inotrem media release, data from this trial were published in the peer review journal Intensive Care Medicine.
- 30 Sep 2018 Results presented in an Inotrem media release.
- 30 Sep 2018 According to an Inotrem media release, data from this study were presented at the annual congress of the International Sepsis Forum.